🚀 VC round data is live in beta, check it out!
Novo Nordisk Valuation Multiples
Discover revenue and EBITDA valuation multiples for Novo Nordisk and similar public comparables like Unilever, Pfizer, Gilead Sciences, Bristol-Myers Squibb and more.
Novo Nordisk Overview
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Founded
1931
HQ
Employees
69.5K
Website
Financials (LTM)
EV
$182B
Novo Nordisk Financials
Novo Nordisk reported last 12-month revenue of $48B and EBITDA of $23B.
In the same LTM period, Novo Nordisk generated $38B in gross profit, $23B in EBITDA, and $16B in net income.
Revenue (LTM)
Novo Nordisk P&L
In the most recent fiscal year, Novo Nordisk reported revenue of $49B and EBITDA of $24B.
Novo Nordisk expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $48B | XXX | $49B | XXX | XXX | XXX |
| Gross Profit | $38B | XXX | $39B | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $23B | XXX | $24B | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 50% | XXX | XXX | XXX |
| EBIT Margin | 41% | XXX | 41% | XXX | XXX | XXX |
| Net Profit | $16B | XXX | $16B | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| Net Debt | — | — | $15B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Novo Nordisk Stock Performance
Novo Nordisk has current market cap of $166B, and enterprise value of $182B.
Market Cap Evolution
Novo Nordisk's stock price is $37.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $182B | $166B | 0.0% | XXX | XXX | XXX | $3.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNovo Nordisk Valuation Multiples
Novo Nordisk trades at 3.8x EV/Revenue multiple, and 7.9x EV/EBITDA.
EV / Revenue (LTM)
Novo Nordisk Financial Valuation Multiples
As of March 23, 2026, Novo Nordisk has market cap of $166B and EV of $182B.
Equity research analysts estimate Novo Nordisk's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novo Nordisk has a P/E ratio of 10.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $166B | XXX | $166B | XXX | XXX | XXX |
| EV (current) | $182B | XXX | $182B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBIT | 9.3x | XXX | 9.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 4.7x | XXX | XXX | XXX |
| P/E | 10.5x | XXX | 10.3x | XXX | XXX | XXX |
| EV/FCF | 35.4x | XXX | 40.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Novo Nordisk Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Novo Nordisk Margins & Growth Rates
Novo Nordisk's revenue in the last 12 month declined by (7%).
Novo Nordisk's revenue per employee in the last FY averaged $0.7M.
Novo Nordisk's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novo Nordisk's rule of X is 31% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Novo Nordisk Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (7%) | XXX | (10%) | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | (8%) | XXX | (14%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Novo Nordisk Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Unilever | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer | XXX | XXX | XXX | XXX | XXX | XXX |
| Gilead Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Bristol-Myers Squibb | XXX | XXX | XXX | XXX | XXX | XXX |
| Amgen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novo Nordisk M&A Activity
Novo Nordisk acquired XXX companies to date.
Last acquisition by Novo Nordisk was on XXXXXXXX, XXXXX. Novo Nordisk acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Novo Nordisk
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNovo Nordisk Investment Activity
Novo Nordisk invested in XXX companies to date.
Novo Nordisk made its latest investment on XXXXXXXX, XXXXX. Novo Nordisk invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Novo Nordisk
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Novo Nordisk
| When was Novo Nordisk founded? | Novo Nordisk was founded in 1931. |
| Where is Novo Nordisk headquartered? | Novo Nordisk is headquartered in Denmark. |
| How many employees does Novo Nordisk have? | As of today, Novo Nordisk has over 69K employees. |
| Who is the CEO of Novo Nordisk? | Novo Nordisk's CEO is Maziar Mike Doustdar. |
| Is Novo Nordisk publicly listed? | Yes, Novo Nordisk is a public company listed on NYSE. |
| What is the stock symbol of Novo Nordisk? | Novo Nordisk trades under NVO ticker. |
| When did Novo Nordisk go public? | Novo Nordisk went public in 1981. |
| Who are competitors of Novo Nordisk? | Novo Nordisk main competitors are Unilever, Pfizer, Gilead Sciences, Bristol-Myers Squibb. |
| What is the current market cap of Novo Nordisk? | Novo Nordisk's current market cap is $166B. |
| What is the current revenue of Novo Nordisk? | Novo Nordisk's last 12 months revenue is $48B. |
| What is the current revenue growth of Novo Nordisk? | Novo Nordisk revenue growth (NTM/LTM) is (7%). |
| What is the current EV/Revenue multiple of Novo Nordisk? | Current revenue multiple of Novo Nordisk is 3.8x. |
| Is Novo Nordisk profitable? | Yes, Novo Nordisk is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novo Nordisk? | Novo Nordisk's last 12 months EBITDA is $23B. |
| What is Novo Nordisk's EBITDA margin? | Novo Nordisk's last 12 months EBITDA margin is 48%. |
| What is the current EV/EBITDA multiple of Novo Nordisk? | Current EBITDA multiple of Novo Nordisk is 7.9x. |
| What is the current FCF of Novo Nordisk? | Novo Nordisk's last 12 months FCF is $5B. |
| What is Novo Nordisk's FCF margin? | Novo Nordisk's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Novo Nordisk? | Current FCF multiple of Novo Nordisk is 35.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.